Solid Biosciences Announces Inducement Grant Under Nasdaq Rule 5635(c)(4) - July 01, 2024

CHARLESTOWN, Mass., July 01, 2024-- Solid Biosciences Inc. (Nasdaq: SLDB), a company specializing in precision genetic medicines for neuromuscular and cardiac diseases, has announced the awarding of 11,847 restricted stock units (RSUs) to a recently hired employee.

The RSUs will vest in four equal parts on each yearly anniversary of the grant date over four years, contingent on the employee’s ongoing service with the company.

This grant follows the guidelines of the Company's 2024 Inducement Stock Incentive Plan and serves as an incentive for the employee’s decision to join Solid Biosciences, aligning with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences is dedicated to the development of gene therapy candidates aimed at treating a variety of conditions. Their portfolio includes SGT-003, targeting Duchenne muscular dystrophy (Duchenne), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), and AVB-401 for BAG3-mediated dilated cardiomyopathy, along with other assets focusing on severe cardiac diseases. The company combines expertise from multiple fields such as science, technology, and disease management to address rare neuromuscular and cardiac diseases. Founded by individuals closely affected by these conditions, Solid Biosciences aims to enhance the quality of life for patients suffering from these serious disorders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!